Summary

EC508 is an investigational synthetic peptide analogue of dynorphin A developed as a non-opioid analgesic. It is designed to produce pain relief through biased kappa-opioid receptor agonism while avoiding the respiratory depression, tolerance, and addiction potential of traditional opioids. The compound is at an early development stage with no published human clinical trial data. It is not a licensed medicine and is sold for research purposes only.

Mechanism

EC508 is a synthetic analogue of dynorphin A (1-13), an endogenous opioid peptide that preferentially activates kappa-opioid receptors. It is designed as a biased agonist, activating G-protein-mediated analgesic signalling while minimising β-arrestin2 recruitment (associated with dysphoric and hallucinogenic effects of traditional kappa agonists). EC508 does not significantly activate mu-opioid receptors, potentially avoiding respiratory depression, tolerance, and dependence. The compound may also interact with other pain-signalling receptors. This mechanism is scientifically plausible but not yet validated by independent peer-reviewed research or clinical trials.

Protocols

No established or researched protocols exist for EC508. The compound is investigational with no approved dosing in any context. Any doses discussed in online communities are speculative and unsupported by clinical data. All information for research reference only — no human consumption or medical use is implied.

EC508 occupies a grey area in UK law. It is not a controlled substance, but it is not a licensed medicine and is not MHRA-approved. Sale with therapeutic claims (particularly for pain relief) could trigger MHRA enforcement under medicines regulations. As an investigational analgesic with no published clinical data, any non-research use is unsupported and potentially unsafe.

Vendor notes

No UK vendors are verified for EC508 supply. As an early-stage investigational compound with no published clinical data, any product sold as 'EC508' should be treated with extreme caution. Authenticity and purity cannot be verified without specialised analytical testing.

References

  1. Vanderah TW. Dynorphins and pain. Clin J Pain. 2010;26(7):609-612. doi:10.1097/AJP.0b013e3181ead6a7
  2. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Pharmacol Rev. 2010;62(2):227-282. doi:10.1124/pr.108.000066
  3. Margolis EB, et al. The dynorphin/kappa opioid system and addiction. Subst Use Misuse. 2020;55(11):1848-1857. doi:10.1080/10826084.2020.1765803
  4. Mastropietro DJ, et al. Peptide-based analgesics: current developments and future perspectives. J Pharm Pharmacol. 2019;71(12):1785-1797. doi:10.1111/jphp.13152
  5. Eupraxis Pharmaceuticals. Company pipeline information. (Company data — not independently peer-reviewed.)